Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Oct 14, 2026 · Filed Oct 14, 2026
The CEO of Inhibrx Biosciences paid $8.6K out of pocket for Inhibrx Biosciences shares. 1 other person at Inhibrx Biosciences bought some too, in the same month.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$8,576
Shares × reported transaction price
<$25K
+0.1%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
First purchase in 1 month
Confirmed open-market purchases by the same insider in the available history
No
Compared with 4 earlier confirmed purchases
2 distinct insiders in 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
62 days after results of Aug 13, 2026, 30 days before results of Nov 13, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $85.26 on Oct 14, 2026, 201% above its 52-week low and 40% below its high, after a 33% drop over the previous 30 trading days
52-week range $28.36 (Oct 23, 2025) to $141.84 (May 6, 2026), 50% of the way up, from 250 adjusted closes. 30 trading days earlier: $126.70 on Aug 31, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
Bought 62 days after INBX's last results announcement; 74% of its insiders' purchases since 2024 were made within 30 days after one
Compared with every open-market purchase and sale of this company in SEC filings since 2006. A fact about the record, not a signal to trade
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +7.3% | −1.0% | +8.3% |
Past results only. Not a forecast.
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Insider buying
Bought outside the usual windowTraded Oct 14 · filed the same day
The CEO of Inhibrx Biosciences paid $210K out of pocket for Inhibrx Biosciences shares. 1 other person at Inhibrx Biosciences bought some too, in the same month.
Insider buying
Bought outside the usual windowTraded Oct 14 · filed the same day
The CEO of Inhibrx Biosciences paid $8.6K out of pocket for Inhibrx Biosciences shares. 1 other person at Inhibrx Biosciences bought some too, in the same month.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
